Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

panpharma z.i. - cefuroxime (cefuroxime sodium) - powder for solution for injection - 750mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

panpharma z.i. - ceftriaxone (ceftriaxone sodium) - powder for solution for injection - 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 4 mg/ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml - solution for injection - 8 mg/2ml - active: dexamethasone sodium phosphate 4.37 mg/ml equivalent to dexamethasone phosphate 4 mg/ml excipient: citric acid monohydrate creatinin sodium citrate sodium hydroxide water for injection - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy. it should be supplemented with salt and or a mineralocorticoid. when so supplemented dexamethasone is indicated in: · acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy. relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available. primary and secondary adrenocortical insufficiency.

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - heparin sodium 5000 iu/ml (25.0 - 27.8 mg/ml);  ;   - solution for injection - 5000 iu/ml - active: heparin sodium 5000 iu/ml (25.0 - 27.8 mg/ml)     excipient: benzyl alcohol hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - heparin is indicated for the prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism and occlusive vascular disease. it is also used to prevent thromboembolic complications arising from cardiac and vascular surgery, frostbite, dialysis and other perfusion procedures. heparin is also used as an anticoagulant in blood transfusions.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

panpharma - ceftriaxone (ceftriaxone sodium) - powder for solution for injection - 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - oxytocin 10 iu/ml equivalent to 16.6 mcg/ml - solution for injection - 10 iu/ml - active: oxytocin 10 iu/ml equivalent to 16.6 mcg/ml excipient: glacial acetic acid sodium acetate sodium chloride water for injection - antepartum: - induction of labour for medical reasons, e.g. in cases of post-term gestation, premature rupture of the membranes, pregnancy-induced hypertension (pre-eclampsia). - enhancement of labour in selected cases of uterine inertia. - oxytocin panpharma may also be indicated in early stage of pregnancy, as adjunctive therapy for management of incomplete, inevitable or missed abortion. postpartum: - during caesarean section, after the delivery of the child. - prevention and treatment of postpartum uterine atony and haemorrhage.